Please wait while the formulary information is being retrieved.
MEDROXYPROGESTERONE ACETATE (medroxyprogesterone acetate)
- Pregnancy contraception
- Abnormal uterine bleeding due to hormonal imbalance
- Endometrial hyperplasia prevention
- Secondary amenorrhea
- Provera Tablet
- Medroxyprogesterone Tablet
- Medroxyprogesterone Intramuscular Syringe
- Medroxyprogesterone Intramuscular Suspension
- Medroxyprogesterone Im Syringe
- Depo-provera Intramuscular Syringe
- Depo-provera Intramuscular Suspension
- Depo-provera Im Syringe
- By Indication
10 mg tablet
- 1 tablet (10 mg) by oral route once daily
2.5 mg tablet
- 2 tablets (5 mg) by oral route once daily
5 mg tablet
- 1 tablet (5 mg) by oral route once daily
medroxyprogesterone 10 mg tablet
- 1 tablet (10 mg) by oral route once daily
medroxyprogesterone 2.5 mg tablet
- 2 tablets (5 mg) by oral route once daily
medroxyprogesterone 5 mg tablet
- 1 tablet (5 mg) by oral route once daily
150 mg/mL intramuscular syringe
- Inject 1 milliliter (150 mg) by intramuscular route every 3 months
medroxyprogesterone 150 mg/mL intramuscular syringe
- Inject 1 milliliter (150 mg) by intramuscular route every 3 months
150 mg/mL intramuscular suspension
- Inject 1 milliliter (150 mg) by intramuscular route every 3 months
400 mg/mL intramuscular suspension
- Inject 1 milliliter (400 mg) by intramuscular route once a month
medroxyprogesterone 150 mg/mL intramuscular suspension
- Inject 1 milliliter (150 mg) by intramuscular route every 3 months
medroxyprogesterone 400 mg/mL intramuscular suspension
- Inject 1 milliliter (400 mg) by intramuscular route once a month
150 mg/mL intramuscular syringe
- Inject 1 milliliter (150 mg) by intramuscular route every 3 months
150 mg/mL intramuscular syringe
- Inject 1 milliliter (150 mg) by intramuscular route every 3 months
150 mg/mL intramuscular suspension
- Inject 1 milliliter (150 mg) by intramuscular route every 3 months
400 mg/mL intramuscular suspension
- Inject 1 milliliter (400 mg) by intramuscular route once a month
150 mg/mL intramuscular syringe
- Inject 1 milliliter (150 mg) by intramuscular route every 3 months
Abnormal uterine bleeding due to hormonal imbalance
- 2 tablets (5 mg) by oral route once daily for 5 days
- 2 tablets (5 mg) by oral route once daily for 10 days
- 2 tablets (5 mg) by oral route once daily
- 1 tablet (5 mg) by oral route once daily
- 1 tablet (5 mg) by oral route once daily for 5 days
- 1 tablet (5 mg) by oral route once daily for 10 days
- 2 tablets (10 mg) by oral route once daily for 5 days
- 2 tablets (10 mg) by oral route once daily for 10 days
- 1 tablet (10 mg) by oral route once daily
- 2 tablets (10 mg) by oral route once daily
- 1 tablet (10 mg) by oral route once daily for 5 days
- 1 tablet (10 mg) by oral route once daily for 10 days
Endogenous estrogen production test
- 2 tablets (10 mg) by oral route once daily for 5 days
- 2 tablets (10 mg) by oral route once daily for 10 days
- 1 tablet (10 mg) by oral route once daily
- 2 tablets (10 mg) by oral route once daily
- 1 tablet (10 mg) by oral route once daily for 5 days
- 1 tablet (10 mg) by oral route once daily for 10 days
Endometrial hyperplasia prevention
- 2 tablets (5 mg) by oral route once daily
- 1 tablet (5 mg) by oral route once daily
- 1 tablet (5 mg) by oral route once daily for 12 days
- 1 tablet (5 mg) by oral route once daily for 14 days
- 2 tablets (5 mg) by oral route once daily for 12 days
- 2 tablets (5 mg) by oral route once daily for 14 days
- 1 tablet (10 mg) by oral route once daily for 12 days
- 1 tablet (10 mg) by oral route once daily for 14 days
- 2 tablets (10 mg) by oral route once daily for 12 days
- 2 tablets (10 mg) by oral route once daily for 14 days
- 1 tablet (10 mg) by oral route once daily
- 2 tablets (10 mg) by oral route once daily
Endometriosis
- Inject 150 mg by intramuscular route every 3 months
- Inject 0.33 milliliter (50 mg) by intramuscular route once weekly forat least 6 months
- Inject 0.67 milliliter (100 mg) by intramuscular route every 2 weeks for at least 6 months
- Inject 1 milliliter (150 mg) by intramuscular route every 3 months for at least 6 months
Pregnancy contraception
- Inject 150 mg by intramuscular route every 3 months
- Inject 1 milliliter (150 mg) by intramuscular route every 3 months
Secondary amenorrhea
- 2 tablets (5 mg) by oral route once daily for 5 days
- 2 tablets (5 mg) by oral route once daily for 10 days
- 2 tablets (5 mg) by oral route once daily
- 1 tablet (5 mg) by oral route once daily
- 1 tablet (5 mg) by oral route once daily for 5 days
- 1 tablet (5 mg) by oral route once daily for 10 days
- 2 tablets (10 mg) by oral route once daily for 5 days
- 2 tablets (10 mg) by oral route once daily for 10 days
- 1 tablet (10 mg) by oral route once daily
- 2 tablets (10 mg) by oral route once daily
- 1 tablet (10 mg) by oral route once daily for 5 days
- 1 tablet (10 mg) by oral route once daily for 10 days
- sodium tetradecyl sulfate
- Sotradecol
Contraindicated
- Aptivus
- artemether-lumefantrine
- atazanavir
- Atripla
- B cplx-C-St.Johnwrt-K.&S.ginsg
- Banzel
- boceprevir
- bosentan
- calcium-mag-B complex-D3-hrb61
- carbamazepine
- Carbatrol
- Cellcept
- Cellcept Intravenous
- chloramphenicol sod succinate
- clobazam
- Coartem
- Cold & Flu Fighter
- dabrafenib
- darunavir
- efavirenz
- efavirenz-emtricitabin-tenofov
- elvitegr-cobicist-emtric-tenof
- Epitol
- Equetro
- Fatigue Relief Complex
- fosamprenavir
- Grifulvin V
- Gris-peg (ultramicrosize)
- griseofulvin microsize
- griseofulvin ultramicrosize
- Incivek
- Invirase
- isoniazid-rifamp-pyrazinamide
- Kaletra
- Korlym
- Lexiva
- lopinavir-ritonavir
- mifepristone
- modafinil
- Mycobutin
- mycophenolate mofetil
- mycophenolate mofetil HCl
- mycophenolate sodium
- Myfortic
- nelfinavir
- nevirapine
- Norvir
- Norvir Soft Gelatin
- Onfi
- oxcarbazepine
- Oxtellar Xr
- Prezista
- Priftin
- Provigil
- Reyataz
- rifabutin
- Rifadin
- Rifamate
- rifampin
- rifampin-isoniazid
- rifapentine
- Rifater
- ritonavir
- rufinamide
- saquinavir mesylate
- St. John's wort
- Stribild
- Sustiva
- Tafinlar
- Tegretol
- Tegretol Xr
- telaprevir
- tipranavir
- Tracleer
- Trileptal
- Victrelis
- Viracept
- Viramune
- Viramune Xr
- vit C-St. John wort-elder-hb30
- Women's Complex
Severe
Moderate
- Adoxa
- aminophylline
- aprepitant
- Avidoxy
- demeclocycline
- Doryx
- Doxy-100
- doxycycline calcium
- doxycycline hyclate
- doxycycline monohydrate
- Dutoprol
- Elixophyllin
- Emend
- fosaprepitant
- Juxtapid
- lomitapide
- Lopressor
- Lopressor Hct
- metoprolol su-hydrochlorothiaz
- metoprolol succinate
- metoprolol ta-hydrochlorothiaz
- metoprolol tartrate
- Minocin
- minocycline
- Monodox
- Morgidox
- Oracea
- Solodyn
- tetracycline
- Theo-24
- Theochron
- theophylline
- theophylline in dextrose 5 %
- tigecycline
- Toprol Xl
- Tygacil
- Vibramycin
- Carcinoma of breast
- Cerebrovascular disorder
- Porphyria
- Predisposition to thrombosis
- Severe hepatic disease
- Thromboembolic disorder
- Thrombophlebitis
Contraindicated
- Osteopenia
- Osteoporosis
Severe
Moderate
- Breast fibroadenosis
- Depression
- Diabetes mellitus
- Edema
- Family history of malignant tumor of breast
- Hyperlipidemia
- Hypertension
- Weight gain
MEDROXYPROGESTERONE ACETATE (medroxyprogesterone acetate)
- Pregnancy contraception
- Abnormal uterine bleeding due to hormonal imbalance
- Endometrial hyperplasia prevention
- Secondary amenorrhea
- Abdominal distension
- Abnormal vaginal bleeding
- Irregular menstrual periods
- Acute abdominal pain
- Appetite changes
- Dizziness
- Edema
- Fatigue
- General weakness
- Headache disorder
- Injection site sequelae
- Libido changes
- Menstrual disorder
- Myalgias
- Nervousness
- Vaginitis
- Weight gain
- Weight loss
More Frequent
Severe
Less Severe
- Depression
- Abdominal distension
- Acne vulgaris
- Alopecia
- Appetite changes
- Arthralgias
- Cramps in legs
- Dizziness
- Dysmenorrhea
- Dyspepsia
- Edema
- Fatigue
- Hypertonia
- Insomnia
- Irritability
- Mastalgia
- Nausea
- Skin rash
- Vaginal discharge
- Vaginitis
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Anaphylaxis
- Anemia
- Angioedema
- Back pain
- Carcinoma of cervix
- Chest pain
- Cystitis
- Deep venous thrombosis
- Depression
- Disease of liver
- Ectopic pregnancy
- Endometrial hyperplasia
- Erythema multiforme
- Erythema nodosum
- Facial palsy
- Fracture
- Galactorrhea not associated with childbirth
- Hepatitis
- Hypercalcemia
- Hypercortisolism
- Hypersensitivity drug reaction
- Malignant neoplasm of the ovary
- Menorrhagia
- Neoplasm of breast
- Obstructive hyperbilirubinemia
- Optic neuritis
- Osteopenia
- Osteoporosis
- Ovarian cyst
- Pancreatitis
- Papilledema
- Pruritus of skin
- Pulmonary thromboembolism
- Rectal bleeding
- Retinal thrombosis
- Scleroderma
- Seizure disorder
- Skin rash
- Thromboembolic disorder
- Thrombophlebitis
Less Severe
- Abnormal glucose tolerance
- Acne vulgaris
- Alopecia
- Amenorrhea
- Body fluid retention
- Body odor
- Cervical discharge
- Chloasma
- Constipation
- Drowsy
- Dry skin
- Erosion of cervix
- Euphoria
- Fever
- Flushing
- Hirsutism
- Hoarseness
- Hyperglycemia
- Increased libido
- Induration of skin
- Insomnia
- Lactation deficiency
- Limb pain
- Lipodystrophy
- Malaise
- Mastalgia
- Migraine
- Nausea
- Nervousness
- Paresthesia
- Polydipsia
- Pruritus of skin
- Urticaria
- Weight gain
Contraindicated
None
Severe Precaution
Medroxyprogesterone (Inj)
Not indicated before menarche. May affect bone development/density.
No safety and efficacy for use in endometrial or renal carcinoma. Reduces bone mineral density.
- 1 Day – 11 Years
- Not indicated before menarche. May affect bone development/density.
- No safety and efficacy for use in endometrial or renal carcinoma. Reduces bone mineral density.
- 11 Years – 18 Years
- Not indicated before menarche. May affect bone development/density.
- No safety and efficacy for use in endometrial or renal carcinoma. Reduces bone mineral density.
Management or Monitoring Precaution
Medroxyprogesterone (Oral)
Safety and efficacy not established.
- 1 Day – 18 Years
- Safety and efficacy not established.
Medroxyprogesterone
- Severity Level:
2
- Additional Notes: Available data suggest little or no known risk for developmental toxicity
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
Medroxyprogesterone
Human data indicate no known adverse effect on nursing infant
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Excreted | No adverse effect | Human data indicate no known adverse effect on nursing infant |
Contraindicated
None
Precaution Exists
Medroxyprogesterone Ac
Neuro/Psych-The Women's Health Initiative Memory Study demonstrated an increased relative risk (2.05, 95% CI) of probable dementia in the elderly when used in combination with estrogens.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | Y | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- This medication may cause serious bone loss which may not return to normal after you stop using it. The risk of bone loss increases with longer use of this medication. This medication should not be used for longer than 2 years unless other birth control methods will not work for you.<br /><br />An important time when your bones continue to build up is during your teenage and young adult years. Use of this medication may increase the risk of weak/brittle bones (osteoporosis), which can lead to broken bones when you are older. Talk with your doctor about the risks and benefits of this medication and other birth control choices.<br /><br /> Do not use this medication if you smoke cigarettes/use tobacco and are over 35 years old. Smoking raises your risk of stroke, heart attack, blood clots, and high blood pressure from hormonal birth control (such as the pill, patch, ring). The risk of these serious problems increases with age and with the number of cigarettes you smoke. Do not smoke or use tobacco.
| Abnormal uterine bleeding due to hormonal imbalance | |
| N92.4 | Excessive bleeding in the premenopausal period |
| N92.5 | Other specified irregular menstruation |
| N92.6 | Irregular menstruation, unspecified |
| N93.8 | Other specified abnormal uterine and vaginal bleeding |
| N93.9 | Abnormal uterine and vaginal bleeding, unspecified |
| N95.0 | Postmenopausal bleeding |
| Pregnancy contraception | |
| Z30 | Encounter for contraceptive management |
| Z30.01 | Encounter for initial prescription of contraceptives |
| Z30.011 | Encounter for initial prescription of contraceptive pills |
| Z30.013 | Encounter for initial prescription of injectable contraceptive |
| Z30.014 | Encounter for initial prescription of intrauterine contraceptive device |
| Z30.015 | Encounter for initial prescription of vaginal ring hormonal contraceptive |
| Z30.016 | Encounter for initial prescription of transdermal patch hormonal contraceptive device |
| Z30.017 | Encounter for initial prescription of implantable subdermal contraceptive |
| Z30.018 | Encounter for initial prescription of other contraceptives |
| Z30.019 | Encounter for initial prescription of contraceptives, unspecified |
| Z30.4 | Encounter for surveillance of contraceptives |
| Z30.40 | Encounter for surveillance of contraceptives, unspecified |
| Z30.41 | Encounter for surveillance of contraceptive pills |
| Z30.42 | Encounter for surveillance of injectable contraceptive |
| Z30.43 | Encounter for surveillance of intrauterine contraceptive device |
| Z30.430 | Encounter for insertion of intrauterine contraceptive device |
| Z30.431 | Encounter for routine checking of intrauterine contraceptive device |
| Z30.433 | Encounter for removal and reinsertion of intrauterine contraceptive device |
| Z30.44 | Encounter for surveillance of vaginal ring hormonal contraceptive device |
| Z30.45 | Encounter for surveillance of transdermal patch hormonal contraceptive device |
| Z30.46 | Encounter for surveillance of implantable subdermal contraceptive |
| Z30.49 | Encounter for surveillance of other contraceptives |
| Z30.8 | Encounter for other contraceptive management |
| Z30.9 | Encounter for contraceptive management, unspecified |
| Z79.3 | Long term (current) use of hormonal contraceptives |
| Z97.5 | Presence of (intrauterine) contraceptive device |
| Secondary amenorrhea | |
| N91.1 | Secondary amenorrhea |
| N91.2 | Amenorrhea, unspecified |
| 0-9 | A-Z |
|---|---|
| N91.1 | Secondary amenorrhea |
| N91.2 | Amenorrhea, unspecified |
| N92.4 | Excessive bleeding in the premenopausal period |
| N92.5 | Other specified irregular menstruation |
| N92.6 | Irregular menstruation, unspecified |
| N93.8 | Other specified abnormal uterine and vaginal bleeding |
| N93.9 | Abnormal uterine and vaginal bleeding, unspecified |
| N95.0 | Postmenopausal bleeding |
| Z30 | Encounter for contraceptive management |
| Z30.01 | Encounter for initial prescription of contraceptives |
| Z30.011 | Encounter for initial prescription of contraceptive pills |
| Z30.013 | Encounter for initial prescription of injectable contraceptive |
| Z30.014 | Encounter for initial prescription of intrauterine contraceptive device |
| Z30.015 | Encounter for initial prescription of vaginal ring hormonal contraceptive |
| Z30.016 | Encounter for initial prescription of transdermal patch hormonal contraceptive device |
| Z30.017 | Encounter for initial prescription of implantable subdermal contraceptive |
| Z30.018 | Encounter for initial prescription of other contraceptives |
| Z30.019 | Encounter for initial prescription of contraceptives, unspecified |
| Z30.4 | Encounter for surveillance of contraceptives |
| Z30.40 | Encounter for surveillance of contraceptives, unspecified |
| Z30.41 | Encounter for surveillance of contraceptive pills |
| Z30.42 | Encounter for surveillance of injectable contraceptive |
| Z30.43 | Encounter for surveillance of intrauterine contraceptive device |
| Z30.430 | Encounter for insertion of intrauterine contraceptive device |
| Z30.431 | Encounter for routine checking of intrauterine contraceptive device |
| Z30.433 | Encounter for removal and reinsertion of intrauterine contraceptive device |
| Z30.44 | Encounter for surveillance of vaginal ring hormonal contraceptive device |
| Z30.45 | Encounter for surveillance of transdermal patch hormonal contraceptive device |
| Z30.46 | Encounter for surveillance of implantable subdermal contraceptive |
| Z30.49 | Encounter for surveillance of other contraceptives |
| Z30.8 | Encounter for other contraceptive management |
| Z30.9 | Encounter for contraceptive management, unspecified |
| Z79.3 | Long term (current) use of hormonal contraceptives |
| Z97.5 | Presence of (intrauterine) contraceptive device |
Formulary Reference Tool